Citius Pharma completes SPAC merger, forms Citius Oncology; holds ~90% of new public company

Citius Pharmaceuticals, Inc.

Merger closed Aug 12, 2024; Citius Oncology expected to trade on Nasdaq as CTOR on Aug 13.
Citius Pharma owns approximately 90% of Citius Oncology after the merger.
LYMPHIR (denileukin diftitox) approved by FDA for relapsed/refractory cutaneous T-cell lymphoma.
Citius Pharma made $3.8M capital contribution to Citius Oncology via no-interest promissory note.
Amended shared services and registration rights agreements executed; shares subject to 6-month lock-up.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.